271 related articles for article (PubMed ID: 33370378)
1. Observational study on time on treatment with abiraterone and enzalutamide.
Fallara G; Lissbrant IF; Styrke J; Montorsi F; Garmo H; Stattin P
PLoS One; 2020; 15(12):e0244462. PubMed ID: 33370378
[TBL] [Abstract][Full Text] [Related]
2. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.
Franck Lissbrant I; Ventimiglia E; Robinson D; Törnblom M; Hjälm-Eriksson M; Lambe M; Folkvaljon Y; Stattin P
Scand J Urol; 2018 Apr; 52(2):143-150. PubMed ID: 29385878
[TBL] [Abstract][Full Text] [Related]
3. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden.
Fallara G; Alverbratt C; Garmo H; Vikman H; Hjelm Eriksson M; Lissbrant IF; Stattin P
Acta Oncol; 2021 Dec; 60(12):1589-1596. PubMed ID: 34533422
[TBL] [Abstract][Full Text] [Related]
4. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
[TBL] [Abstract][Full Text] [Related]
6. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
[TBL] [Abstract][Full Text] [Related]
7. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
8. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Davies RS; Smith C; Lester JF
Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
[TBL] [Abstract][Full Text] [Related]
11. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
Baillie K; Mueller T; Pan J; Laskey J; Bennie M; Crearie C; Kavanagh K; Alvarez-Madrazo S; Morrison D; Clarke J; Keel A; Cameron D; Wu O; Kurdi A; Jones RJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):653-663. PubMed ID: 32316077
[TBL] [Abstract][Full Text] [Related]
12. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
13. Adoption of Abiraterone and Enzalutamide by Urologists.
Caram MEV; Kaufman SR; Modi PK; Herrel L; Oerline M; Ross R; Skolarus TA; Hollenbeck BK; Shahinian V
Urology; 2019 Sep; 131():176-183. PubMed ID: 31136769
[TBL] [Abstract][Full Text] [Related]
14. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
Hashimoto K; Tabata H; Shindo T; Tanaka T; Hashimoto J; Inoue R; Muranaka T; Hotta H; Yanase M; Kunishima Y; Takahashi A; Masumori N;
Urol Oncol; 2019 Jul; 37(7):485-491. PubMed ID: 31103335
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Schrader AJ; Boegemann M; Ohlmann CH; Schnoeller TJ; Krabbe LM; Hajili T; Jentzmik F; Stoeckle M; Schrader M; Herrmann E; Cronauer MV
Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
[TBL] [Abstract][Full Text] [Related]
16. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.
Caram MEV; Borza T; Min HS; Griggs JJ; Miller DC; Hollenbeck BK; Mukherjee B; Skolarus TA
J Oncol Pract; 2017 Aug; 13(8):e694-e702. PubMed ID: 28628393
[TBL] [Abstract][Full Text] [Related]
17. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.
Banna GL; Urzia V; Benanti C; Pitrè A; Lipari H; Di Quattro R; De Giorgi U; Schepisi G; Basso U; Bimbatti D; Rundo F; Libra M; Malatino L
Support Care Cancer; 2020 Oct; 28(10):4687-4695. PubMed ID: 31960124
[TBL] [Abstract][Full Text] [Related]
18. [Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
Richter I; Dvořák J; Hejzlarová V; Chalupa J; Sochor M; Stankuš I; Barsová L; Holikova M; Forster J; Bartoš J
Klin Onkol; 2016; 29(2):127-32. PubMed ID: 27081803
[TBL] [Abstract][Full Text] [Related]
19. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.
Sonpavde G; Huang A; Wang L; Baser O; Miao R
BJU Int; 2018 Jun; 121(6):871-879. PubMed ID: 29388324
[TBL] [Abstract][Full Text] [Related]
20. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
Zhang T; Zhu J; George DJ; Armstrong AJ
Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
